Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000243746 | SCV000311871 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Gene |
RCV000243746 | SCV000517576 | benign | not specified | 2015-12-02 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Wong Mito Lab, |
RCV000503929 | SCV000598282 | benign | Mitochondrial DNA depletion syndrome 13 | 2017-08-10 | criteria provided, single submitter | reference population | The NM_012160.4:c.465C>T (NP_036292.2:p.Leu155=) [GRCH38: NC_000006.12:g.98926524G>A] variant in FBXL4 gene is interpretated to be a Benign - Stand Alone based on ACMG guidelines (PMID: 25741868). This variant meets one or more of the following evidence codes reported in the ACMG-guideline. BA1:Minor allele frequency is too high for the Mitochondrial DNA depletion syndrome 13. BS2:Observation of the variant is in controls is inconsistent with penetrance of Mitochondrial DNA depletion syndrome 13. BP4:Computational evidence/predictors indicate no impact on the FBXL4 structure, function, or protein-protein interaction. Based on this evidence code ClinGen Pathogenicity Calculator (PMID:28081714) suggested that the variant is Benign - Stand Alone. |
Labcorp Genetics |
RCV000676937 | SCV001724569 | benign | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000676937 | SCV000802756 | benign | not provided | 2016-02-26 | no assertion criteria provided | clinical testing |